These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10446948)

  • 1. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States.
    Obrador GT; Ruthazer R; Arora P; Kausz AT; Pereira BJ
    J Am Soc Nephrol; 1999 Aug; 10(8):1793-800. PubMed ID: 10446948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities to improve the care of patients with kidney transplant failure.
    Gill JS; Abichandani R; Khan S; Kausz AT; Pereira BJ
    Kidney Int; 2002 Jun; 61(6):2193-200. PubMed ID: 12028460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of erythropoietin before the initiation of dialysis and its impact on mortality.
    Fink J; Blahut S; Reddy M; Light P
    Am J Kidney Dis; 2001 Feb; 37(2):348-55. PubMed ID: 11157377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
    Moreno F; Aracil FJ; Pérez R; Valderrábano F
    Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of dialysis and its relationship to dialysis adequacy, anemia management, and serum albumin level.
    Rocco MV; Bedinger MR; Milam R; Greer JW; McClellan WM; Frankenfield DL
    Am J Kidney Dis; 2001 Oct; 38(4):813-23. PubMed ID: 11576885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in anemia at initiation of dialysis in the United States.
    Obrador GT; Roberts T; St Peter WL; Frazier E; Pereira BJ; Collins AJ
    Kidney Int; 2001 Nov; 60(5):1875-84. PubMed ID: 11703606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-end-stage renal disease care in the United States: a state of disrepair.
    Obrador GT; Arora P; Kausz AT; Pereira BJ
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S44-54. PubMed ID: 11443767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center.
    Arora P; Obrador GT; Ruthazer R; Kausz AT; Meyer KB; Jenuleson CS; Pereira BJ
    J Am Soc Nephrol; 1999 Jun; 10(6):1281-6. PubMed ID: 10361866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severity of AIDS and the response to EPO in uremia.
    Ifudu O; Matthew JJ; Mayers JD; Macey LJ; Brezsnyak W; Reydel C; McClendon E; Surgrue T; Rao S; Friedman EA
    Am J Kidney Dis; 1997 Jul; 30(1):28-35. PubMed ID: 9214398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
    Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
    Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [REIN Report 2011--summary].
    Couchoud C; Lassalle M; Jacquelinet C
    Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time.
    Lu WX; Jones-Burton C; Zhan M; Salzberg DJ; Moore J; Fink JC
    Nephron Clin Pract; 2005; 101(2):c79-86. PubMed ID: 15976508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.
    Xue JL; St Peter WL; Ebben JP; Everson SE; Collins AJ
    Am J Kidney Dis; 2002 Dec; 40(6):1153-61. PubMed ID: 12460033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sociodemographic and geographic predictors of quality of care in United States patients with end-stage renal disease due to lupus nephritis.
    Plantinga LC; Drenkard C; Patzer RE; Klein M; Kramer MR; Pastan S; Lim SS; McClellan WM
    Arthritis Rheumatol; 2015 Mar; 67(3):761-72. PubMed ID: 25692867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients.
    Beusterien KM; Nissenson AR; Port FK; Kelly M; Steinwald B; Ware JE
    J Am Soc Nephrol; 1996 May; 7(5):763-73. PubMed ID: 8738812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients.
    Stack AG; Bloembergen WE
    Am J Kidney Dis; 2001 Nov; 38(5):992-1000. PubMed ID: 11684552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
    Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
    JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1996 peritoneal dialysis--core indicators report.
    Flanigan MJ; Rocco MV; Frankenfield DL; Bailie G; Frederick PR; Prowant BF; Taylor L
    Am J Kidney Dis; 1998 Jul; 32(1):E3. PubMed ID: 10074586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.